Aura Biosciences (AURA) has upcoming FDA regulatory milestones for Belzupacap Sarotalocan (AU-011). The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by Aura Biosciences (AURA).
Over the past two years, Aura Biosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Belzupacap and AU-011. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Belzupacap Sarotalocan (AU-011) FDA Regulatory Timeline and Events
Belzupacap Sarotalocan (AU-011) is a drug developed by Aura Biosciences for the following indication: Non-Muscle Invasive Bladder Cancer (NMIBC).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Belzupacap Sarotalocan (AU-011)
- Announced Date:
- June 1, 2026
- Target Action Date:
- H2 2027
- Estimated Target Date Range:
- July 1, 2027 - December 31, 2027
- Indication:
- Non-Muscle Invasive Bladder Cancer (NMIBC)
Announcement
Aura Biosciences Announced that the Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.
AI Summary
Aura Biosciences said that enrollment is now complete in its registration-enabling Phase 3 CoMpass trial, which included 108 patients. The company’s next major milestone is topline data from the 15-month primary endpoint, which it expects to report in the second half of 2027.
This timeline means investors and researchers will have to wait several years for the key results that will help show how well the treatment works. Aura said the study is moving forward as planned, and the upcoming data readout will be an important step for the program.
Read Announcement- Drug:
- Belzupacap Sarotalocan (AU-011)
- Announced Date:
- June 1, 2026
- Indication:
- Non-Muscle Invasive Bladder Cancer (NMIBC)
Announcement
Aura Biosciences, Inc. announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma.
AI Summary
Aura Biosciences said it has finished enrolling 108 patients in its Phase 3 CoMpass trial. The study is testing belzupacap sarotalocan, or bel-sar, as a first treatment for patients with early choroidal melanoma, a rare eye cancer. The trial is registration-enabling, which means the results could support future approval if the treatment works well.
The company said the main 15-month results from the study are expected in the second half of 2027. Aura is now focused on collecting data from the enrolled patients and following the trial as planned. The goal is to see whether bel-sar can offer a new frontline option for people with this cancer.
Read Announcement- Drug:
- Belzupacap Sarotalocan (AU-011)
- Announced Date:
- May 4, 2026
- Indication:
- Non-Muscle Invasive Bladder Cancer (NMIBC)
Announcement
Aura Biosciences, Inc announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succeeds Elisabet de los Pinos, Ph.D., the Company's founder, who stepped down from her roles as Chief Executive Officer and President and member of the Board of Directors on the same date.
AI Summary
Aura Biosciences, Inc. announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer, President, and a member of the Board, effective April 30, 2026. Holles is a seasoned industry executive with deep rare disease operational and commercialization experience and will lead the company’s next growth phase.
She succeeds Elisabet de los Pinos, Ph.D., the company’s founder, who stepped down from her roles as CEO, President, and board member on the same date. The leadership change comes as Aura reports accelerating patient screening that has pushed enrollment in the Phase 3 CoMpass trial to near completion.
Aura highlighted bel-sar as a potential first frontline vision-preserving therapy in this setting, and the company expects Holles to help advance development and prepare for potential commercialization efforts.
Read Announcement
AU-011 FDA Regulatory Timeline and Events
AU-011 is a drug developed by Aura Biosciences for the following indication: Uveal Melanoma (Includes Choroidal Melanoma).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- AU-011
- Announced Date:
- March 24, 2025
- Indication:
- Uveal Melanoma (Includes Choroidal Melanoma)
Announcement
Aura Biosciences, Inc. announced positive data from a completed Phase 1 window of opportunity trial of bel-sar (AU-011) in patients with NMIBC.
AI Summary
Aura Biosciences, Inc. announced positive data from its completed Phase 1 window of opportunity trial of bel-sar (AU-011) in patients with non-muscle invasive bladder cancer (NMIBC). The trial assessed the safety and clinical activity of a single low dose of bel-sar, administered with light activation, in both intermediate- and high-risk NMIBC patients. Notably, in the intermediate-risk subgroup, 4 out of 5 patients showed a clinical complete response, with no tumor cells found on histopathological evaluation, while several patients exhibited tumor shrinkage observed during cystoscopy. The treatment also produced robust cell-mediated immune responses, with significant infiltration of CD8+ and CD4+ T-cells in the tumor microenvironment, suggesting an induced immune-driven urothelial field effect. The favorable safety profile—with only minimal Grade 1 drug-related adverse events—underscores its potential as a paradigm shifting, front-line treatment option for NMIBC. Future Phase 1b/2 trials are planned to further assess its efficacy.
Read Announcement- Drug:
- AU-011
- Announced Date:
- March 3, 2025
- Indication:
- Uveal Melanoma (Includes Choroidal Melanoma)
Announcement
Aura Biosciences, Inc. announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology (EAU) Congress being held March 21-24, 2025, in Madrid, Spain.
AI Summary
Aura Biosciences, Inc. announced that additional Phase 1 data for bel-sar (AU-011) in treating non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology Congress. The event will take place in Madrid, Spain, from March 21 to 24, 2025. During the congress, Aura will participate in the EAU Research Forum where late-breaker results on the safety and efficacy of bel-sar will be shared. The Phase 1 trial is an open-label, multi-center study that assesses the feasibility and safety of using bel-sar as a pre-surgical treatment before the standard transurethral resection of bladder tumor (TURBT). The presentation aims to highlight bel-sar’s biological activity, its dual mechanism of action, and its role in triggering an immune response, potentially paving the way for improved treatment strategies in bladder cancer care.
Read Announcement- Drug:
- AU-011
- Announced Date:
- September 12, 2024
- Indication:
- Uveal Melanoma (Includes Choroidal Melanoma)
Announcement
Aura Biosciences, Inc. announced positive Phase 2 end of study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and life-threatening ocular cancer.
AI Summary
Aura Biosciences, Inc. announced promising Phase 2 study results for bel-sar (AU-011) as a first-line treatment for early-stage choroidal melanoma, a serious ocular cancer. The study showed an 80% tumor control rate among eligible patients, with responders experiencing a near complete halt in tumor growth. In addition, the treatment preserved visual acuity in 90% of patients, even among those at high risk for vision loss due to proximity to critical eye structures such as the fovea or optic disc.
The trial, which included 22 patients and monitored them over 12 months, also demonstrated a highly favorable safety profile with no treatment-related serious adverse events. These results highlight bel-sar’s potential as a first-in-class therapy that effectively manages tumor growth while preserving vision, a significant advance compared to the current standard care that often leads to severe visual impairment.
Read Announcement
Free AURA Stock Alerts